If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
278
results.
Updated on
31/08/2026 [07:07:00]
Results 200 to 225 of 278
Absstract of: AU2025225163A1
This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.
Absstract of: US20260241030A1
The present invention refers to a multifunctional CNC*-Au-based nanoplatform, related conjugates and/or composition containing thereof.The present invention also refers to the use of such a multifunctional CNC*-Au-based nanoplatform, related conjugates and/or composition containing thereof in medicine
Absstract of: US20260240788A1
The present invention deals with a method for preparing a nanosystem vehicle encapsulating one or more active ingredients, preferably selected from pharmaceutical active ingredients, subsequently comprising cryomilling one or more amphiphilic compounds, one or more of said active ingredients and a frozen aqueous medium in order to obtain a uniform frozen mixture, and forming said nanosystem vehicle upon thawing. The invention further relates to a nanosystem vehicle obtainable by the aforementioned method and its uses for therapeutic and non-therapeutic applications.
Absstract of: US20260242784A1
The present invention provides an interfering RNA for inhibiting B7-H3 expression, use thereof, and a method for preparing cells with reduced B7-H3 expression. The interfering RNA is siRNA, a target sequence of which comprises nucleotide sequences set forth in SEQ ID NOs: 1-25. The interfering RNA can effectively inhibit B7-H3 gene expression, thus being useful for preventing or treating B7-H3 related diseases.
Absstract of: AU2025223661A1
The present disclosure provides cationic lipid compounds having the following Structure (I): where G1, G2, R1, R2, R3a, R3b, R3c, R3d, R4a, R4b, R4c, R4d, L1, L2, and L3 are as defined herein. The present disclosure also discloses pharmaceutically acceptable salts or stereoisomers thereof. Also provided by the present disclosure are uses of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: AU2026213957A1
The present invention relates to lipid nanoparticles (LNP) or compositions thereof for delivery of mRNA molecules encoding CAR, nucleic acid molecule, and/or therapeutic agents to selected targets, such as cells. Thus, in various aspects, the present invention also provides methods of preventing or treating diseases or disorders in a 5 subject in need thereof using the said LNPs or compositions thereof. ug u g
Absstract of: US20260242769A1
0000 Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Absstract of: US20260241040A1
0000 The design, synthesis, and functionalization of a conjugate including a tumor-targeting near-infrared (NIR) dye and a therapeutic agent and/or a diagnostic agent, whereby the NIR dye can function to target the therapeutic agent and/or diagnostic agent to tumor cells.
Absstract of: AU2026213966A1
Abstract Fusosome compositions and methods are described herein. Abstract ug u g
Absstract of: US20260242440A1
0000 The present invention relates to the field of neurodegenerative processes and means to provide protection against the same. In particular, the present invention relates to polypeptides, fusion proteins, and other compounds interacting with the N-terminal domain of transient receptor potential melastatin subfamily member 4 (TRPM4), which are capable of interfering with NMDA receptor mediated neurotoxicity. The present invention also relates to nucleic acids encoding the aforementioned polypeptides or fusion proteins, compositions comprising the same and the use of said polypeptides, fusion proteins, and other compounds in methods for treating or preventing a disease of the human or animal body, for example in a method of treating diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) or stroke.
Absstract of: US20260240776A1
The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
Absstract of: WO2026171285A1
Provided are a preparation method for a cellulose nanocrystal-based hydrogel, and an application thereof. The hydrogel preparation method comprises: (1) adding cerium ions to a cellulose nanocrystal (CNC) suspension, and controlling the pH to be neutral, to obtain a cerium oxide-modified CNC suspension; (2) mixing the modified CNC suspension in step (1) with a CNC suspension which has not undergone the modification in step (1), to obtain a CNC mixed suspension; and (3) mixing the CNC mixed suspension in step (2) with a prepolymer, and irradiating with ultraviolet light, to obtain a hydrogel.
Absstract of: WO2026171211A1
Disclosed are a hMPV fusion protein F variant, an mRNA vaccine, and a use thereof. The hMPV fusion protein F variant has an amino acid residue difference at one or more sites relative to an hMPV fusion protein F having the accession number AGJ74096.1 in the GenBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is as shown in SEQ ID NO: 1 or 2. The mRNA vaccine designed on the basis of the hMPV fusion protein F variant can induce a strong specific antibody response, and the persistence of an antibody in vivo is strong. The induced antibody can better neutralize an hMPV strain and control the amplification of the hMPV in the lungs. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for prevention of hMPV infection-related diseases and development of combination vaccines.
Absstract of: WO2026170677A1
Disclosed in the present invention are a J-aggregation-induced emission photosensitizer with NIR-II emission, and a pharmaceutical composition constructed thereby, a preparation method therefor and the use thereof. The photosensitizer can produce cytotoxic type I active oxygen upon light irradiation, and exhibits excellent fluorescence imaging capability in an NIR-II region and superior phototherapeutic performance. The photosensitizer is further co-assembled with sorafenib into a pharmaceutical composition, which has J-aggregation-induced secondary self-assembly property, enables long-term imaging at a tumor site, fulfills dual functions of NIR-II fluorescence imaging and tumor therapy, and exhibits good stability and low toxic and side effects, thereby holding a wide prospect for clinical application.
Absstract of: AU2026210866A1
Abstract The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery. ug u g
Absstract of: US20260240786A1
0000 The invention generally relates to polymer-based nano-structures. More particularly, the invention relates to novel, surface-functionalized, guest-host polymer nano-assemblies and nano-delivery vehicles useful in diverse fields including drug delivery, diagnostics and specialty materials. The nano-assemblies and nano-delivery vehicles of the invention are afforded via simplify and reliable approaches.
Absstract of: WO2026174151A1
The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.
Absstract of: WO2026171955A1
The present invention relates to a "one-pot" method for preparing an aqueous composition of nanoparticles of copolymers with amphiphilic blocks and comprising polypeptide units, said nanoparticles comprising at least one active principle encapsulated therein, said method comprising: - at least one step (E1) consisting in preparing a solution (S1) comprising at least one active principle and at least one hydrophilic polymer (P1) comprising at least one amine function; and - at least one step (E2), in an aqueous solvent, consisting in placing the solution (S1) in the presence of at least one hydrophobic α-amino acid N-carboxyanhydride monomer.
Absstract of: WO2026173309A1
The present invention relates to naltrexone-fatty acid conjugate nanoparticles and a long-acting injection thereof. More specifically, the present invention provides naltrexone-fatty acid conjugate nanoparticles and a long-acting injection composition thereof, the nanoparticles comprising a naltrexone-fatty acid conjugate in which a fatty acid is bonded to naltrexone or a pharmaceutically acceptable salt thereof, and being formed by self-assembly of the conjugate according to a pH change. The composition according to the present invention has improved bioavailability, half-life, injectability, and the like, and exhibits excellent long-term sustained release characteristics, and thus can improve medication compliance of patients with alcohol dependence or opioid dependence.
Absstract of: US20260240889A1
Methods and compositions for the transamniotic delivery of mRNA encoding alpha-1 antitrypsin protein to a fetus for the prenatal treatment of alpha-1 antitrypsin deficiency.
Absstract of: WO2026171948A1
The present invention relates to a "one-pot" method for preparing an aqueous solution of nanoparticles of copolymers with amphiphilic blocks and comprising polypeptide units, said nanoparticles comprising a chemical agent grafted thereto, said method comprising: • at least one step (E1), in an aqueous solvent, consisting in placing at least one hydrophilic polymer of formula (I): A-NH2, wherein A represents a natural or synthetic polymeric radical comprising the repetition of at least one unit selected from the group consisting of acrylates, ethylenes, oxyalkylenes, ethers, esters, sugars and amino acids, in the presence of at least one hydrophobic α-amino acid N-carboxyanhydride monomer, in order to obtain a copolymer of formula (II), and • at least one functionalization step (E2), in an aqueous solvent, consisting in placing said copolymer of formula (II) in the presence of a chemical agent comprising at least one carboxylic acid function or carboxylic acid derivative function allowing coupling with said copolymer of formula (II).
Absstract of: WO2026172347A1
A copolymer nanohydrogel comprising chains made of structural units corresponding to (i) at least one macromonomer consisting of a polyether block copolymer with acrylamide end groups, and (ii) an N-alkylated (meth)acrylamide monomer; characterized in that the chains of the copolymer nanohydrogel are connected by at least one crosslinker that contains biodegradable ester bond. A nanohydrogel comprising poorly water-soluble pharmaceutically active compound, a process for preparing the nanohydrogel, pharmaceutical composition thereof, and method of using the nanohydrogels are also provided by the invention.
Absstract of: WO2026174041A1
Porous nanofibrous/microfibrous spheres are provided as well as methods of use thereof and methods of making. In certain embodiments, the method of synthesis comprises a) applying inner air, outer air, and a nanofiber/microfiber suspension to a sphere generator, wherein the nanofiber/microfiber suspension comprises nanofiber/microfiber segments, and b) collecting the spheres from an outlet nozzle of the sphere generator in a media having a temperature of less than about -20°C (e.g., liquid nitrogen), thereby synthesizing the porous nanofibrous/microfibrous spheres.
Absstract of: WO2026170578A1
The present invention belongs to the technical field of the preparation of Dendrobium officinale polysaccharides, and specifically relates to a Dendrobium officinale polysaccharide nanoparticle and a preparation method therefor. The method for preparing the Dendrobium officinale polysaccharide nanoparticle comprises: firstly, extracting Dendrobium officinale polysaccharides by using a non-ionic surfactant-assisted ultrasonic-complex enzyme method, and purifying same to obtain a Dendrobium officinale polysaccharide extract; then dissolving the Dendrobium officinale polysaccharide extract in water to obtain solution 1; dissolving a modified polyacrylic resin in an organic solvent to obtain solution 2; dropwise adding solution 1 to solution 2 under stirring, and performing ultrasonic treatment for 20-30 min after the dropwise addition; and performing spray drying to obtain the final product. The method for extracting Dendrobium officinale polysaccharides provided in the present invention can effectively increase the yield of polysaccharides, and can also improve the inhibition rate of the Dendrobium officinale polysaccharide extract against α-glucosidase. The prepared Dendrobium officinale polysaccharide extract nanoparticle exhibits a good hypoglycemic effect.
Nº publicación: WO2026174220A1 20/08/2026
Applicant:
MASSACHUSETTS INST OF TECHNOLOGY [US]
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Absstract of: WO2026174220A1
Single polymer chain nanoparticles (SPCNs) formed by a random heteropolymer composed of three or more components have been developed and shown to display similar levels of hydration frustration as proteins. These SPCNs can be categorized into three types, based on whether either hydrophobic or hydrophilic residues, or both types, display frustrated states. A series of physicochemical rules that determine the state of these SPCNs are proposed. The generality of these rules are demonstrated via atomistic molecular dynamics simulations and simplified Monte Carlo models of SCPNs with different backbones and residues. This disclosure provides insights into the design of SPCNs, an emerging polymer modality that achieves the ease and cost of fabrication of polymeric material with the functionality of biological proteins.
BOPI
Electronic site
